Share the Video:

Effects of psilocybin-assisted psychotherapy on personality and their relationship with self-compassion among individuals with alcohol use disorder

Broc A Pagni

Emerging research suggests psilocybin-assisted psychotherapy (PAP) may precipitate enduring changes in personality and self-compassion in various clinical populations. However, PAP-induced personality changes have yet to be characterized in patients with alcohol use disorder (AUD), and the relationship with self-compassion remains unknown. In this double-blind, placebo-controlled trial with 84 individuals, psilocybin occasioned alterations to multiple dimensions of personality in patients with AUD, and these changes are tightly linked with improvements in self-compassion. Future studies with larger samples are needed to replicate this work and determine the relevance, if any, of psilocybin-induced changes in personality and self-compassion on AUD outcomes.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Psychohistoriographic approaches to Psychedelic Assisted Psychotherapy in Jamaica

Resurgence in psychedelic assisted psychotherapy (PAP) shows promise in treating mental illnesses, integrating psilocybin with Psychohistoriographic Brief Therapy (PBT) in a structured treatment protocol. Caribbean programs must prioritize safety and

Winston De La Haye

PS2023 Harm Reduction Health Conditions Ketamine Psychedelic Assisted Therapy Research and Science Therapy Ethics

Ketamine-assisted psychotherapy in adolescents with multiple psychiatric diagnoses

KAP program offers innovative treatment for adolescents with emotional issues, focusing on family involvement. Successes and challenges of this unique approach are discussed.

Phil Wolfson

PS2023 Harm Reduction Health Equity Policy and Advocacy Psychedelic Assisted Therapy Research and Science Therapy Ethics

Telemedicine models for supporting psychedelic therapy

Panel explores how telemedicine can enhance psychedelic therapy practice, discussing benefits and risks of virtual care in light of pandemic-induced regulatory changes and improved meeting tech.

Juan Pablo Cappello, Jonathan Sabbagh

PS2023 Harm Reduction Policy and Advocacy Psychedelic Assisted Therapy Public Benefit Research and Science Substance Use Disorder

Panel discussion and Q&A with addiction researchers

Substance use disorder cases doubled during the pandemic, with over 100,000 drug overdose deaths in 2020. Research explores psychedelic-assisted therapy as a potential paradigm shift in addiction treatment efficacy.

Michael Bogenschutz, Matthew Johnson, Deborah Mash, Peter S. Hendricks

PS2023 Health Conditions Psilocybin Psychedelic Assisted Therapy Research and Science Therapy Ethics

Panel discussion on psilocybin therapy for cancer patients and palliative care

Dr. Smith and Dr. Jones explore the latest research on psychedelic therapy and its potential impact on mental health during the PS2023 conference.

Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider

PS2023 Harm Reduction Integration Psilocybin Psychedelic Assisted Therapy Research and Science Resources for Therapists

Psychedelic-Assisted Training: Outcomes from a World-First Study

Psychedelic therapies re-emerge in clinical research, prompting exploration of therapist training methods and competencies. A study involving psilocybin support for therapists shows potential benefits for psychedelic therapy implementation.

Paul Liknaitzky

PS2023 Harm Reduction Health Conditions Integration Psilocybin Psychedelic Assisted Therapy Research and Science

Pilot study of Psilocybin-Assisted Therapy in Hospice care (PATH): preliminary feasibility, safety and efficacy considerations

Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.

Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna

PS2023 Depression Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research and Science Therapy Ethics

Psilocybin-assisted Therapy for Major Depressive Disorder: Clinical Results and Cases From a Placebo-controlled, Fixed-order Trial

Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.

Jordan Sloshower, Stephanie Kilpatrick

PS2023 Depression Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research and Science Substance Use Disorder

Psychedelics: Spirituality, Mindfulness, and Mortality – Personal reflections and visions for the future

Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.

Roland Griffiths

Effects of psilocybin-assisted psychotherapy on personality and their relationship with self-compassion among individuals with alcohol use disorder

Become a MAPS Member with a monthly donation

Related Videos